CFL1 and pancreatic ductal adenocarcinoma: This study applied the method of EnVision immunohistochemistry to investigate the expression levels of UGP2 and CFL1 in 106 cases of pancreatic ductal carcinoma, 35 cases of paracancerous tissues, 55 cases of benign lesions, and 13 cases of normal pancreatic tissues, as well as their clinical pathological significance.